menu
  • Home
  • About Us »
    « Back
    • Overview
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Corporate Compliance
    • Contact
  • Research »
    « Back
    • Diseases and Conditions
    • Drug Development Pipeline
    • Drug Discovery
    • Clinical Trials
    • Publications
    • Investigator Initiated Studies
  • Partnerships
  • Careers
  • Citizenship »
    « Back
    • Social Responsibility
    • Scientist Development Program
    • Aclaris Support
  • Insights
  • Investors »
    « Back
    • Investor Overview
    • Stock Information
    • Press Releases
    • Events
    • SEC Filings
    • Corporate Governance
    • Investor Presentations
    • Investor FAQs
    • Email Alerts
  • Media resources
  • Contact us
  • Home
  • About Us »
    « Back
    • Overview
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Corporate Compliance
    • Contact
  • Research »
    « Back
    • Diseases and Conditions
    • Drug Development Pipeline
    • Drug Discovery
    • Clinical Trials
    • Publications
    • Investigator Initiated Studies
  • Partnerships
  • Careers
  • Citizenship »
    « Back
    • Social Responsibility
    • Scientist Development Program
    • Aclaris Support
  • Insights
  • Investors »
    « Back
    • Investor Overview
    • Stock Information
    • Press Releases
    • Events
    • SEC Filings
    • Corporate Governance
    • Investor Presentations
    • Investor FAQs
    • Email Alerts
  • Diseases and Conditions
  • Drug Development Pipeline
  • Drug Discovery
  • Clinical Trials
  • Publications

Posters and publications

MK2 pathway inhibitor

Selective Inhibition of the p38α MAPK–MK2 Axis Inhibits Inflammatory Cues Including Inflammasome Priming Signals »

Wang C, Hockerman S, Jacobsen EJ, et al. J Exp Med. 2018;215(5):1315-1325.
doi: 10.1084/jem.20172063.

Selective p38α MAPK Inhibitor Shows Promise »

McHugh, J. Nature Reviews Rheumatol. 2018;14(6): 321. 

Inhibition of the Stromal p38MAPK/MK2 Pathway Limits Breast Cancer Metastases and Chemotherapy-Induced Bone Loss »

Murali B, Ren Q, Luo X, et al. Cancer Res. 2018;78(19):5618-5630. doi: 10.1158/0008-5472.CAN-18-0234

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the MK2 Inhibitor ATI-450 in Healthy Subjects: A Placebo-Controlled, Randomized Phase 1 Study »

Gordon D, Monahan J, et al. Clinical Pharmacology: Advances and Applications 2021:13 123–134

    • Terms of use
    • Privacy policy
    • Contact us
    • Fraudulent Activity Notice
    © 2023 Aclaris Therapeutics, Inc. All rights reserved. Unless otherwise noted, all trademarks referenced on this page are owned by Aclaris Therapeutics.